145 related articles for article (PubMed ID: 35065946)
1. Prediction of neoplastic progression in Barrett's esophagus using nanoscale nuclear architecture mapping: a pilot study.
Thota PN; Nasibli J; Kumar P; Sanaka MR; Chak A; Zhang X; Liu X; Uttam S; Liu Y
Gastrointest Endosc; 2022 Jun; 95(6):1239-1246. PubMed ID: 35065946
[TBL] [Abstract][Full Text] [Related]
2. A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus.
Critchley-Thorne RJ; Davison JM; Prichard JW; Reese LM; Zhang Y; Repa K; Li J; Diehl DL; Jhala NC; Ginsberg GG; DeMarshall M; Foxwell T; Jobe BA; Zaidi AH; Duits LC; Bergman JJ; Rustgi A; Falk GW
Cancer Epidemiol Biomarkers Prev; 2017 Feb; 26(2):240-248. PubMed ID: 27729357
[TBL] [Abstract][Full Text] [Related]
3. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
[TBL] [Abstract][Full Text] [Related]
4. Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus.
Bird-Lieberman EL; Dunn JM; Coleman HG; Lao-Sirieix P; Oukrif D; Moore CE; Varghese S; Johnston BT; Arthur K; McManus DT; Novelli MR; O'Donovan M; Cardwell CR; Lovat LB; Murray LJ; Fitzgerald RC
Gastroenterology; 2012 Oct; 143(4):927-35.e3. PubMed ID: 22771507
[TBL] [Abstract][Full Text] [Related]
5. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
[TBL] [Abstract][Full Text] [Related]
6. Symptoms and endoscopic features at barrett's esophagus diagnosis: implications for neoplastic progression risk.
Coleman HG; Bhat SK; Murray LJ; McManus DT; O'Neill OM; Gavin AT; Johnston BT
Am J Gastroenterol; 2014 Apr; 109(4):527-34. PubMed ID: 24589668
[TBL] [Abstract][Full Text] [Related]
7. A biomarker panel predicts progression of Barrett's esophagus to esophageal adenocarcinoma.
Duits LC; Lao-Sirieix P; Wolf WA; O'Donovan M; Galeano-Dalmau N; Meijer SL; Offerhaus GJA; Redman J; Crawte J; Zeki S; Pouw RE; Chak A; Shaheen NJ; Bergman JJGHM; Fitzgerald RC
Dis Esophagus; 2019 Jan; 32(1):. PubMed ID: 30496496
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Mutational Testing of Preneoplastic Barrett's Mucosa by Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Endoscopic Samples for Detection of Concurrent Dysplasia and Adenocarcinoma in Barrett's Esophagus.
Del Portillo A; Lagana SM; Yao Y; Uehara T; Jhala N; Ganguly T; Nagy P; Gutierrez J; Luna A; Abrams J; Liu Y; Brand R; Sepulveda JL; Falk GW; Sepulveda AR
J Mol Diagn; 2015 Jul; 17(4):412-9. PubMed ID: 26068095
[TBL] [Abstract][Full Text] [Related]
9. Barrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression.
Klaver E; Bureo Gonzalez A; Mostafavi N; Mallant-Hent R; Duits LC; Baak B; Böhmer CJM; van Oijen AHAM; Naber T; Scholten P; Meijer SL; Bergman JJGHM; Pouw RE;
United European Gastroenterol J; 2021 Oct; 9(8):929-937. PubMed ID: 34228885
[TBL] [Abstract][Full Text] [Related]
10. Validation of a biomarker panel in Barrett's esophagus to predict progression to esophageal adenocarcinoma.
Eluri S; Klaver E; Duits LC; Jackson SA; Bergman JJ; Shaheen NJ
Dis Esophagus; 2018 Nov; 31(11):. PubMed ID: 29635420
[TBL] [Abstract][Full Text] [Related]
11. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
[TBL] [Abstract][Full Text] [Related]
12. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
[TBL] [Abstract][Full Text] [Related]
13. Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma.
Stachler MD; Camarda ND; Deitrick C; Kim A; Agoston AT; Odze RD; Hornick JL; Nag A; Thorner AR; Ducar M; Noffsinger A; Lash RH; Redston M; Carter SL; Davison JM; Bass AJ
Gastroenterology; 2018 Jul; 155(1):156-167. PubMed ID: 29608884
[TBL] [Abstract][Full Text] [Related]
14. The Amsterdam ReBus progressor cohort: identification of 165 Barrett's surveillance patients who progressed to early neoplasia and 723 nonprogressor patients.
Duits LC; Klaver E; Bureo Gonzalez A; Boerwinkel DF; Ten Kate FJW; Offerhaus GJA; Meijer SL; Visser M; Seldenrijk CA; Krishnadath KK; Schoon EJ; Weusten BLAM; Mallant-Hent RC; Pouw RE; Bergman JJGHM
Dis Esophagus; 2019 Nov; 32(9):. PubMed ID: 29873685
[TBL] [Abstract][Full Text] [Related]
15. Alterations to the Esophageal Microbiome Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma.
Snider EJ; Compres G; Freedberg DE; Khiabanian H; Nobel YR; Stump S; Uhlemann AC; Lightdale CJ; Abrams JA
Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1687-1693. PubMed ID: 31466948
[TBL] [Abstract][Full Text] [Related]
16. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.
Gaddam S; Singh M; Balasubramanian G; Thota P; Gupta N; Wani S; Higbee AD; Mathur SC; Horwhat JD; Rastogi A; Young PE; Cash BD; Bansal A; Vargo JJ; Falk GW; Lieberman DA; Sampliner RE; Sharma P
Gastroenterology; 2013 Sep; 145(3):548-53.e1. PubMed ID: 23714382
[TBL] [Abstract][Full Text] [Related]
17. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
[TBL] [Abstract][Full Text] [Related]
18. Yield of Repeat Endoscopy in Barrett's Esophagus with No Dysplasia and Low-Grade Dysplasia: A Population-Based Study.
Visrodia K; Iyer PG; Schleck CD; Zinsmeister AR; Katzka DA
Dig Dis Sci; 2016 Jan; 61(1):158-67. PubMed ID: 25956705
[TBL] [Abstract][Full Text] [Related]
19. Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study.
Sikkema M; Looman CW; Steyerberg EW; Kerkhof M; Kastelein F; van Dekken H; van Vuuren AJ; Bode WA; van der Valk H; Ouwendijk RJ; Giard R; Lesterhuis W; Heinhuis R; Klinkenberg EC; Meijer GA; ter Borg F; Arends JW; Kolkman JJ; van Baarlen J; de Vries RA; Mulder AH; van Tilburg AJ; Offerhaus GJ; ten Kate FJ; Kusters JG; Kuipers EJ; Siersema PD
Am J Gastroenterol; 2011 Jul; 106(7):1231-8. PubMed ID: 21577245
[TBL] [Abstract][Full Text] [Related]
20. Independent Validation of a Tissue Systems Pathology Assay to Predict Future Progression in Nondysplastic Barrett's Esophagus: A Spatial-Temporal Analysis.
Frei NF; Konte K; Bossart EA; Stebbins K; Zhang Y; Pouw RE; Critchley-Thorne RJ; Bergman JJGHM
Clin Transl Gastroenterol; 2020 Oct; 11(10):e00244. PubMed ID: 33108124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]